Diabetes and Technology: The Role of Artificial Intelligence, Continuous Glucose Monitors, and Insulin Pumps in Modern Care

Abstract

The increasing global prevalence of diabetes and the substantial burden it places on individuals and healthcare systems underscore the urgent need for advanced technological solutions. This review highlights the transformative role of artificial intelligence (AI), continuous glucose monitors (CGMs), and insulin pumps in modern diabetes care, addressing gaps in accessibility, integration, and long-term efficacy. By synthesizing recent advancements and challenges, this review aims to provide a comprehensive perspective on how these technologies can revolutionize diabetes management. The review explores the precision of AI-driven algorithms in insulin dosing and glucose prediction, the benefits of CGMs in real-time glycemic monitoring, and the advancements in insulin pump technology, including hybrid closed-loop systems. It also examines the integration of these technologies into cohesive ecosystems, their impact on patient outcomes, and the disparities in access that hinder widespread adoption. Key topics include AI’s role in personalized treatment, the clinical efficacy of CGMs, and the convergence of pumps and sensors for automated insulin delivery (AID). Additionally, the review addresses ethical considerations, data privacy concerns, and the psychosocial effects of technology adoption. Insights from clinical trials and real-world studies demonstrate significant improvements in glycemic control, quality of life, and patient engagement, while also identifying persistent challenges such as cost, interoperability, and user adherence. Future research should prioritize large-scale, diverse clinical trials to validate AI models and ensure equitable access to these technologies across populations. Innovations in multimodal data integration, fully AID systems, and emerging wearable technologies hold promises for further personalizing diabetes care. Collaborative efforts among clinicians, researchers, and policymakers will be essential to overcome existing barriers and fully realize the potential of AI, CGMs, and insulin pumps in transforming diabetes worldwide.